| Characteristic . | DTG + TAF/FTC (n = 15) . | DTG/3TC (n = 16) . | P value . |
|---|---|---|---|
| Age, years | 28 (24–43) | 27 (24–35) | 0.861 |
| Risk for HIV-1 infection, MSM | 15 | 14 | |
| Smoker, yes | 3 (20.0) | 4 (25.0) | 0.739 |
| Recreational drugs, yes | 1 (6.7) | 4 (25.0) | 0.333 |
| BMI, kg/m2 | 23.5 (22.5–25.2) | 22.6 (19.9–25.9) | 0.512 |
| CD4+ T cell counts/mm3 | 394 (239–558) | 454 (347–638) | 0.295 |
| CD4+/CD8+ ratio | 0.57 (0.28–1.08) | 0.50 (0.42–0.73) | 0.843 |
| BP HIV-1-RNA, log10 copies/mL | 4.81 (4.30–5.43) | 4.76 (4.09–5.23) | 0.469 |
| SP HIV-1-RNA, log10 copies/mL | 3.39 (2.78–3.54) | 3.80 (2.51–5.21) | 0.276 |
| Characteristic . | DTG + TAF/FTC (n = 15) . | DTG/3TC (n = 16) . | P value . |
|---|---|---|---|
| Age, years | 28 (24–43) | 27 (24–35) | 0.861 |
| Risk for HIV-1 infection, MSM | 15 | 14 | |
| Smoker, yes | 3 (20.0) | 4 (25.0) | 0.739 |
| Recreational drugs, yes | 1 (6.7) | 4 (25.0) | 0.333 |
| BMI, kg/m2 | 23.5 (22.5–25.2) | 22.6 (19.9–25.9) | 0.512 |
| CD4+ T cell counts/mm3 | 394 (239–558) | 454 (347–638) | 0.295 |
| CD4+/CD8+ ratio | 0.57 (0.28–1.08) | 0.50 (0.42–0.73) | 0.843 |
| BP HIV-1-RNA, log10 copies/mL | 4.81 (4.30–5.43) | 4.76 (4.09–5.23) | 0.469 |
| SP HIV-1-RNA, log10 copies/mL | 3.39 (2.78–3.54) | 3.80 (2.51–5.21) | 0.276 |
Data expressed as median (IQR) or n (%). DTG/3TC, dolutegravir/lamivudine.
| Characteristic . | DTG + TAF/FTC (n = 15) . | DTG/3TC (n = 16) . | P value . |
|---|---|---|---|
| Age, years | 28 (24–43) | 27 (24–35) | 0.861 |
| Risk for HIV-1 infection, MSM | 15 | 14 | |
| Smoker, yes | 3 (20.0) | 4 (25.0) | 0.739 |
| Recreational drugs, yes | 1 (6.7) | 4 (25.0) | 0.333 |
| BMI, kg/m2 | 23.5 (22.5–25.2) | 22.6 (19.9–25.9) | 0.512 |
| CD4+ T cell counts/mm3 | 394 (239–558) | 454 (347–638) | 0.295 |
| CD4+/CD8+ ratio | 0.57 (0.28–1.08) | 0.50 (0.42–0.73) | 0.843 |
| BP HIV-1-RNA, log10 copies/mL | 4.81 (4.30–5.43) | 4.76 (4.09–5.23) | 0.469 |
| SP HIV-1-RNA, log10 copies/mL | 3.39 (2.78–3.54) | 3.80 (2.51–5.21) | 0.276 |
| Characteristic . | DTG + TAF/FTC (n = 15) . | DTG/3TC (n = 16) . | P value . |
|---|---|---|---|
| Age, years | 28 (24–43) | 27 (24–35) | 0.861 |
| Risk for HIV-1 infection, MSM | 15 | 14 | |
| Smoker, yes | 3 (20.0) | 4 (25.0) | 0.739 |
| Recreational drugs, yes | 1 (6.7) | 4 (25.0) | 0.333 |
| BMI, kg/m2 | 23.5 (22.5–25.2) | 22.6 (19.9–25.9) | 0.512 |
| CD4+ T cell counts/mm3 | 394 (239–558) | 454 (347–638) | 0.295 |
| CD4+/CD8+ ratio | 0.57 (0.28–1.08) | 0.50 (0.42–0.73) | 0.843 |
| BP HIV-1-RNA, log10 copies/mL | 4.81 (4.30–5.43) | 4.76 (4.09–5.23) | 0.469 |
| SP HIV-1-RNA, log10 copies/mL | 3.39 (2.78–3.54) | 3.80 (2.51–5.21) | 0.276 |
Data expressed as median (IQR) or n (%). DTG/3TC, dolutegravir/lamivudine.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
